

FEB 17 2004

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

FEB 17 2004

Total Number of Pages in This Submission

Application Number

10/660,113

Filing Date

September 10, 2003

First Named Inventor

Kavita Shah

Group Art Unit

1645

Examiner Name

Unassigned

Attorney Docket Number

36-001720US

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> PTO-1449 form, Cited References and receipt acknowledgment postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
	Authorization to Charge Deposit Account Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.	
	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT


Firm or Individual name	Angela P. Horne, Ph.D., Reg. No. 41,079, Quine Intellectual Property Law Group, P.C.
Signature	<i>Angela P. Horne, PhD</i>
Date	February 13, 2004

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

2-13-04

Typed or printed name	Evelyn Gomez
Signature	<i>Evelyn Gomez</i>
Date	February 13, 2004



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313-1450, on February 13, 2004

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By _____

Evelyn Gomez

Attorney Docket No. 36-001720US
Client Ref. No. P0046US20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Kavita Shah, et al.

Application No.: 10/660,113

Filed: September 10, 2003

For: HIGHLY SPECIFIC MODULATORS
OF GTPASES FOR TARGET
VALIDATION

Examiner: Unassigned

Art Unit: 1645

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action on the merits per 37 CFR 1.97(b)(3). However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Angela P. Horne, Ph.D.
Reg. No. 41,079

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/660,113
		Filing Date	September 10, 2003
		First Named Inventor	Kavita Shah
		Group Art Unit	1645
		Examiner Name	Unassigned
		Attorney Docket Number	36-001720US
		Date Submitted	February 13, 2004

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
1	6,390,821	^	B1	Princeton University	05-21-2002	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T
	2	BENARD et al., "Potential Drug Targets: Small GTPases that Regulate Leukocyte Function" Trends Pharmacol. Science, 20:365-370 (1999).					
	3	BISHOP et al., "Design of Allele-Specific Inhibitors to Probe Protein Kinase Signaling" Current Biology, 8:257-266 (1998).					
	4	BISHOP et al., "Generation of Monospecific Nanomolar Tyrosine Kinase Inhibitors via a Chemical Genetic Approach", J. Am. Chem. Soc., 121:627-631 (1999).					
	5	BISHOP et al., "A chemical switch for inhibitor-sensitive alleles of any protein kinase" Nature, 407: 395-401 (2000).					
	6	BISHOP et al., "Unnatural Ligands for Engineered Proteins: New Tools for Chemical Genetics" Annu. Rev. Biophys. Biomol. Struct., 29: 577-606 (2000).					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO O P E INFORMATION DISCLOSURE STATEMENT BY APPLICANT FEB 17 2004 <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/660,113
		Filing Date	September 10, 2003
		First Named Inventor	Kavita Shah
		Group Art Unit	1645
		Examiner Name	Unassigned
		Attorney Docket Number	36-001720US
		Date Submitted	February 13, 2004

7	BOQUET et al., "Rho GTP-Binding Proteins as Targets for Microbial Pathogens" Prog. Mol. Subcell. Biol., 22:183-199 (1999).
8	BOS, "Ras Oncogenes in Human Cancer: A Review" Cancer Res., 49:4682-4689 (1989).
9	BOURNE et al., "The GTPase Superfamily: Conserved Structure and Molecular Mechanism" Nature, 349:117-27 (1991).
10	BARBACID "Ras Oncogenes: Their Role in Neoplasia" Eur. J. Clin. Invest., 20:225-235 (1990).
11	CARROLL et al., "Role of Rab9 GTPase in Facilitating Receptor Recruitment by TIP47", Science, 292:1373-1376 (2001).
12	CARROLL et al., "Chemical Inhibition of the Pho85 Cyclin-Dependent Kinase Reveals a Role in the Environmental Stress Response", Proc. Natl. Acad. Sci. USA, 98:22:12578-12583 (2001).
13	COOL et al., "The Ras Mutant D119N is Both Dominant Negative and Activated" Mol. Cell. Biol., 19: 6297-6305 (1999).
14	COWARD et al., "Controlling Signaling with a Specifically Designed Gi-Coupled Receptor" Proc. Natl. Acad. Sci. USA, 95: 352-357 (1998).
15	DE GUNZBURG, "Proteins of the Ras Pathway as Novel Potential Anticancer Therapeutic Targets" Cell Biol. Toxicol., 15:345-358 (1999).
16	DOWNDWARD, "Targeting Ras Signaling Pathways in Cancer Therapy" Nat. Rev. Cancer, 3:11-22 (2003).
17	GILLESPIE et al., "Engineering of the Myosin-I β Nucleotide-binding Pocket to Create Selective Sensitivity to N ⁶ -Modified ADP Analogs", The Journal of Biological Chemistry, 274:31373-31381 (1999).
18	HABELHAH et al., "ERK Phosphorylation Drives Cytoplasmic Accumulation of HnRNP-K and Inhibition of mRNA Translation", Nature Cell Biology, 3:325-330 (2001).
19	HABELHAH et al., "Identification of New JNK Substrate Using ATP Pocket Mutant JNK and a Corresponding ATP Analogue", The Journal of Biological Chemistry, 276:2:18090-18095 (2001).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

Application Number	10/660,113
Filing Date	September 10, 2003
First Named Inventor	Kavita Shah
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	36-001720US
Date Submitted	February 13, 2004

FEB 17 2004
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

20	HOLT et al., "A Chemical-Genetic Strategy Implicates Myosin-1c in Adaptation by Hair Cells" Cell, 108: 371-381 (2002).
21	HWANG & MILLER, "A Mutation that Alters the Nucleotide Specificity of Elongation Factor Tu, a GTP Regulatory Protein" J. Biol. Chem., 262:13081-5 (1987).
22	LIN et al., "Design of Allele-Specific Protein Methyltransferase Inhibitors" J. Am. Chem. Soc., 123: 11608-13 (2001).
23	LIU et al., "A Molecular Gate which Controls Unnatural ATP Analogue Recognition by the Tyrosine Kinase v-Src", Bioorganic & Medicinal Chemistry, 6:1219-1226 (1998).
24	LIU et al., "Engineering Src Family Protein Kinases with Unnatural Nucleotide Specificity", Chemistry & Biology, 5:91-101 (1998).
25	LIU et al., "Src-Abl Tyrosine Kinase Chimeras: Replacement of the Adenine Binding Pocket of c-Abl with v-Src to Swap Nucleotide and Inhibitor Specificities", Biochemistry, 39:14400-14408 (2000).
26	NEVES et al., "G Protein Pathways", Science, 296:1636-1638 (2002).
27	PEET et al., "Engineering Novel Specificities for Ligand-Activated Transcription in the Nuclear Hormone Receptor RXR" Chem. Biol., 5:13-21 (1998).
28	POLAKIS AND MCCORMICK, "Structural Requirements for the Interaction of p21 ^{ras} with GAP, Exchange Factors, and its Biological Effector Target" J. Biol. Chem., 268:9157-9160 (1993).
29	SCHREIBER, "Chemical Genetics Resulting from a Passion for Synthetic Organic Chemistry" Bioorganic Med. Chem., 6: 1127-52 (1998).
30	SHAH & SHOKAT, "A Chemical Genetic Screen for Direct v-Src Substrates Reveals Ordered Assembly of a Retrograde Signaling Pathway" Chemistry & Biology, 9: 35-47 (2002).
31	SHAH et al., "Engineering Unnatural Nucleotide Specificity for Rous Sarcoma Virus Tyrosine Kinase to Uniquely Label its Direct Substrates" Proc. Natl. Acad. Sci. USA, 94: 3565-3570 (1997).
32	SHOKAT & VELLECA, "Novel Chemical Genetic Approaches to the Discovery of Signal Transduction Inhibitors" Drug Discovery Today, 7: 872-879 (2002).

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

Application Number	10/660,113
Filing Date	September 10, 2003
First Named Inventor	Kavita Shah
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	36-001720US
Date Submitted	February 13, 2004

O I P INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
FEB 17 2004

(use as many sheets as necessary)

33	SPENCER et al., "Controlling Signal Transduction with Synthetic Ligands" Science, 262:1019-1024 (1993).
34	SPRANG, "G Proteins Mechanisms: Insights from Structural Analysis" Annual Rev. Biochem., 66:639-678 (1997).
35	ULRICH et al., "Towards the Engineering of an Orthogonal Protein Kinase/Nucleotide Triphosphate Pair" Tetrahedron, 56:9495-9502 (2000).
36	VENTER et al., "The Sequence of the Human Genome", Science, 291:1304-51 (2001).
37	VETTER & WITTINGHOFER, "The Guanine Nucleotide-Binding Switch in Three Dimensions" Science, 294:1299-3304 (2001).
38	WALTER et al., "The Oncogenic Activation of Human p21 ^{ras} by a Novel Mechanism" Science, 233:649-652 (1986).
39	WEIJLAND et al., "Elongation Factor Tu D138N, a Mutant with Modified Substrate Specificity, as a Tool to Study Energy Consumption in Protein Biosynthesis" Biochemistry, 33:10711-10717 (1994).
40	WEIJLAND et al., "Toward a Model for the Interaction Between Elongation Factor Tu and the Ribosome", Science, 259:1311-1314 (1993).
41	WOLFMAN, "Ras Isoform-Specific Signaling: Location, Location, Location" Science's STKE, 96:1-4 (2001).
42	YU et al., "Characterization of a Gα _i Mutant That Binds Xanthine Nucleotides", Journal of Biological Chemistry, 272:18015-18019 (1997).

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.